OptiNose (OPTN) to Release Quarterly Earnings on Thursday

OptiNose (NASDAQ:OPTN) is projected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect OptiNose to post earnings of ($0.67) per share and revenue of $21.02 million for the quarter.

OptiNose Trading Up 6.6 %

Shares of OPTN opened at $5.62 on Wednesday. The company has a market cap of $56.54 million, a price-to-earnings ratio of -1.34 and a beta of -0.17. The business’s fifty day simple moving average is $5.96 and its two-hundred day simple moving average is $8.87. OptiNose has a 12 month low of $4.82 and a 12 month high of $31.50.

Insider Buying and Selling at OptiNose

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the transaction, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.30% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. HC Wainwright upped their target price on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Lake Street Capital lowered their price objective on shares of OptiNose from $45.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, January 16th. Finally, Piper Sandler cut their target price on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.